2-hydroxy-2-(4-nitrophenyl)propionic acid | 81168-94-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-2-(4-nitrophenyl)propionic acid
• 英文别名: 2-hydroxy-2-(4-nitrophenyl)propanoic Acid
• CAS: 81168-94-7
• 化学式: C₉H₉NO₅
• 分子量: 211.174
• InChiKey: BUYKQTWMLZLHDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-hydroxy-2-(4-nitrophenyl)propionic acid 在 吡啶 、 氯化亚砜 作用下， 反应 34.5h， 生成 ZM 147376
  参考文献：
  名称：

  Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens

  摘要：

  Antiandrogenic activity is observed in anilides containing a tertiary hydroxyl group, and these compounds are used to define a pharmacophore in terms of their physicochemical properties. Infrared spectroscopy shows that these anilides exist in a single conformation, which exerts a powerful influence on the hydrogen-bond donor ability of the hydroxyl group in a model system. Arguments are presented which suggest that hydrogen-bonding ability is an important contributor to biological activity. Compounds were synthesized that reproduced these properties in series not containing an amide bond. Such compounds were found to exhibit good antiandrogen activity. We suggest that quantitative information on hydrogen bonding might also be useful in other systems.

  DOI：

  10.1021/jm00105a067
• 作为产物：
  描述：

  1-cyano-1-(4-nitrophenyl)ethyl diethyl phosphate 在 盐酸 作用下， 以 水 为溶剂， 反应 12.0h， 以70%的产率得到2-hydroxy-2-(4-nitrophenyl)propionic acid
  参考文献：
  名称：

  N-heterocyclic carbenes mediated cyano-phosphorylation of ketones

  摘要：

  Cyanation-O-protection reaction of ketones with different cyanide sources catalyzed by N-heterocyclic carbenes is reported. Under the catalysis of 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, various ketones coupled with diethyl cyanophosphonate to produce cyanohydrin-O-phosphates with a quaternary carbon center in moderate to excellent yield. Furthermore, the reaction can be scaled-up easily and high yield maintained. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.08.073

文献信息

• [EN] SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF<br/>[FR] LIEURS AUTO-IMMOLABLES CONTENANT DES DÉRIVÉS D'ACIDE MANDÉLIQUE, CONJUGUÉS MÉDICAMENT-LIGAND POUR THÉRAPIES CIBLÉES, ET LEURS UTILISATIONS
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015038426A1

  公开（公告）日：2015-03-19

  The invention provides a therapeutic drug and targeting conjugate, pharmaceutical compositions containing these conjugates in pharmaceutical composition, and uses of these conjugates in anti-neoplastic and other therapeutic regimens. Also provided are novel intermediates thereof. The conjugates provide a therapeutic drug fragment or prodrug fragment bound to a targeting moiety via a linker which comprises a substrate cleavable by a protease such as Cathepsin B. The targeting moiety is a ligand which targets a cell surface molecule, such as a cell surface receptor on an anti-neoplastic cell. The ligand may function solely as a targeting moiety or may itself have a therapeutic effect. Following administration of the therapeutic drug and targeting conjugate of formula I and exposure of the conjugate to the protease specific for the substrate, the linker is cleaved and the targeting moiety is separated from the conjugate, which causes the drug fragment or prodrug fragment to convert to the drug or prodrug. The recited conjugates are useful in anti-neoplastic therapies. Also provided are methods of making the therapeutic drug and targeting conjugates and intermediates thereof, and kits comprising the therapeutic drug and targeting conjugates.

  该发明提供了一种治疗药物和靶向共轭物，包含这些共轭物的药物组合物，以及这些共轭物在抗肿瘤和其他治疗方案中的用途。还提供了其新颖的中间体。这些共轭物通过一个由蛋白酶如半胱氨酸蛋白酶B可切割的底物组成的连接物将治疗药物片段或前药片段与靶向基团结合。靶向基团是一个以细胞表面分子为靶点的配体，例如抗肿瘤细胞上的细胞表面受体。该配体可能仅作为靶向基团，也可能本身具有治疗效果。在给药公式I的治疗药物和靶向共轭物并使共轭物暴露于特异于底物的蛋白酶的情况下，连接物被切割，靶向基团与共轭物分离，导致药物片段或前药片段转化为药物或前药。所述的共轭物在抗肿瘤疗法中很有用。还提供了制备治疗药物和靶向共轭物及其中间体的方法，以及包含治疗药物和靶向共轭物的试剂盒。
• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20160251376A1

  公开（公告）日：2016-09-01

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。
• [EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
  申请人：NIMBUS LAKSHMI INC

  公开号：WO2015131080A1

  公开（公告）日：2015-09-03

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物抑制TYK2并治疗TYK2介导的疾病的方法。
• [EN] ENDOPARASITIC DEPSIPEPTIDES<br/>[FR] DEPSIPEPTIDES ENDOPARASITAIRES
  申请人：ZOETIS SERVICES LLC

  公开号：WO2019217449A1

  公开（公告）日：2019-11-14

  The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R1, R2, R3, R4, L1, and L2 are as defined herein. The present invention also contemplates compositions, methods of treatment, and uses as a medicament to treat an animal for an endoparasitic infection with a Formula (1 ) compound.

  本发明提供了公式（1）的环状脱氨肽、其立体异构体以及兽医可接受的盐，其中R1、R2、R3、R4、L1和L2中的每一个如本文所定义。本发明还涉及组合物、治疗方法和用作药物治疗动物内寄生虫感染的公式（1）化合物。
• Synthesis of α-Hydroxycarboxylic Acids from Various Aldehydes and Ketones by Direct Electrocarboxylation: A Facile, Efficient and Atom Economy Protocol
  作者：Kishanpal Singh、Harvinder Singh Sohal、Baljit Singh

  DOI：10.14233/ajchem.2021.23090

  日期：2021.3.31

  In present work, the formation of α-hydroxycarboxylic acids have been described from various aromatic aldehydes and ketones via direct electrocarboxylation method with 80-92% of yield without any side product and can be purified by simple recrystallization using sacrificial Mg anode and Pt cathode in an undivided cell, CO2 at (1 atm) was continuously bubbled in the cell throughout the reaction using

  在目前的工作中，已经描述了通过直接电羧化方法从各种芳香醛和酮形成α-羟基羧酸，收率80-92％，没有任何副产物，并且可以使用牺牲镁阳极和铂阴极通过简单的重结晶来纯化在整个反应过程中，使用四丙基氯化铵作为乙腈中的支持电解质，在未分割的电池中，以（1 atm）的CO2在电池中连续鼓泡。所合成的化合物收率相当出色，且纯度较高。电羧化化合物的表征是通过红外、核磁共振（1H 和 13C）、质量和元素分析等光谱技术来完成的。